

University of Groningen

## Changing images of cytomegalovirus infection

Maar, Eltjo Fredericus de

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2003

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Maar, E. F. D. (2003). *Changing images of cytomegalovirus infection*. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## **CHAPTER 3**

### **INCREASED INTESTINAL PERMEABILITY DURING CYTOMEGALOVIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS**

E.F. de Maar, J.H. Kleibeuker, W. Boersma-van Ek, T.H. The, and W.J. van Son

Transplant International 1996; 9:576-580

**ABSTRACT**

Cytomegalovirus (CMV) infections in renal transplant recipients can affect the gastrointestinal tract, but significant clinical manifestations are seldom seen. We hypothesize that subclinical involvement of the gastrointestinal tract may be quite frequent during CMV infection. In order to study this we measured intestinal permeability by calculating the urinary lactulose mannitol (LM) excretion ratio after oral administration of lactulose and mannitol (normal  $< 0.030$ ) in patients with symptomatic and asymptomatic CMV infection. A total of 111 patients were enrolled into the study, 104 of them were tested on postoperative day (pod) 10. Twenty-nine patients developed CMV infection, 12 of them could be studied with the permeability test (median pod 40). Another nine patients without CMV infection were also studied at day 40 and served as controls. The LM ratio increased significantly during CMV infection compared to measurements before active infection (median 0.060 vs. 0.030,  $P < 0.01$ ), and was significantly higher during the infection than in the control group (median 0.007,  $P < 0.01$ ). No correlation could be found between the LM ratio and viral load, humoral response to the virus, or symptomatology of infection. We conclude that an increased intestinal permeability is found in a substantial number of patients with an active, albeit asymptomatic, CMV infection after renal transplantation. Pathophysiological mechanisms and clinical implications remain speculative but will be subject to further study.

### 3.1 INTRODUCTION

Cytomegalovirus infection is the most frequent infectious complication after renal transplantation. Although CMV infections after renal transplantation are frequently seen, a substantial number of them are asymptomatic. When CMV infection causes disease most patients exhibit a so-called self-limiting CMV syndrome consisting of spiking fever, arthralgia, leukocytopenia, thrombocytopenia, and elevated serum liver enzymes. Less common manifestations involve the gastrointestinal tract, the lungs, the eyes, the kidney, the heart and the nervous system. Clinical manifestations of gastrointestinal involvement include ulcerative lesions anywhere along the gastrointestinal tract, intestinal pneumatosis [1], pancreatitis and hepatitis.

We hypothesize that there is frequent subclinical organ involvement during CMV infection in renal transplant patients. This would be in accordance with the systemic nature of this type of infection. For example van Son et al. [2] have already demonstrated that when subjected to sensitive pulmonary function tests, a majority of patients with an active CMV infection have pulmonary dysfunction, even without pulmonary symptoms. Thus far subclinical involvement of the gastrointestinal tract during CMV infection has not been studied.

The epithelium of the gastrointestinal tract has important transport functions, but the barrier function with respect to luminal molecules is at least as important. Intestinal permeability relates to the barrier function and the permeation of marker molecules is used to measure the permeability. Most intestinal permeability tests are based on the quantitation in the urine of marker molecules ingested orally. However, not only the permeability of the intestinal surface but many other factors such as gastric emptying, dilution by secretions and renal clearance determine the excretion of marker molecules. Using two markers that differ in permeability but are affected equally by all the other factors can eliminate these factors. This principle is called differential permeability testing. The excretion ratio of these two markers has shown to be a reliable test for intestinal permeability. This method of measuring intestinal permeability is widely accepted and used for testing mucosal dysfunction, making more invasive diagnostic procedures unnecessary [3].

In this study we evaluated the subclinical involvement of the gastrointestinal tract in renal transplant recipients with CMV infection by determining intestinal permeability with lactulose and mannitol as markers.

### 3.2 MATERIALS AND METHODS

One hundred eleven patients transplanted between 1990 and 1993 were included in the study. Sixty-five were men. The mean age was 44 years (range: 18-68 years). The median dialysis period pretransplantation was 32 months (range: 0-144 months). There were 101 first transplantations, 9 second and 1 third. Six transplantations were living related. Fifty-three percent of the patients were seropositive for CMV before transplantation. Patients were considered seropositive when IgG antibodies against CMV late antigen (CMV LA) were present. No CMV prophylaxis (acyclovir, ganciclovir or anti-CMV immunoglobulins) was given. Initial immunosuppression consisted of cyclosporine A and low-dose prednisolone. Patients with a second or third transplant received induction therapy with monoclonal antibodies (OKT3), followed by triple therapy (azathioprine, cyclosporine A and low dose prednisolone). All patients gave informed consent before participating in the study.

A differential permeability test was performed to measure intestinal permeability. We used lactulose (342 Da, 0.52 nm) and mannitol (182 Da, 0.40 nm) as markers.

After an overnight fast of at least 6h and with an empty urine bladder, patients drank 100 ml of water containing 10 g lactulose and 0,5 g mannitol. The osmolality of the solution was 255 mosmol/l. No oral intake was allowed during the first 2h after ingestion of the test solution, and subsequently milk or sugars were not allowed until five hours after commencing the test. Urine was collected during a period of five hours after the test solution had been ingested. The volume of the urine collected was recorded and an aliquot was refrigerated at  $-20^{\circ}\text{C}$  until the time of analysis.

The lactulose and mannitol concentrations in the urine were measured by gas liquid chromatography as described by Laker [4] and Laker and Mount [5] respectively, with minor modifications. Briefly, the samples were mixed with internal standard solution ( $\alpha$ -methyl glucose), washed, and dried. Pyridine/hydroxysil (Chromopack, Middelburg, The Netherlands) was added and the specimens and heated at  $60^{\circ}\text{C}$  for 2 h. Samples were analyzed in a Packard 428 chromatograph (Packard-Becker, Delft, The Netherlands) on a 200-cm column of 3% OV-1 (Chromopack, Middelburg, The Netherlands), operated at  $190^{\circ}\text{C}$  for 7 min and at  $250^{\circ}\text{C}$  for 6 min; the temperature was elevated from  $190^{\circ}\text{C}$  to  $250^{\circ}\text{C}$  in 12 min. Mannitol, 1 mmol/l, and lactulose, 1 mmol/l, were used as standard solutions (Janssen Pharmaceutica, Belgium).

The lactulose mannitol excretion ratio (LM ratio) was calculated by dividing the urinary lactulose excretion by the urinary mannitol excretion expressed as percent-

ages of the ingested doses. Normal values are below 0.030 and are independent of renal function. Especially in our patients, who had a broad range of glomerular filtration rates, it was necessary to be very sure about the independency of renal function, as reviewed in the literature [3, 6]. For this reason we measured the LM ratio in 10 non-transplanted patients without gastrointestinal diseases from the outpatient renal clinic and with glomerular filtration rates below 25 ml/min: these ratios were in the normal range.

Diagnosis of active CMV infection was made using the CMV pp65-antigenemia assay, as described by Van der Bij et al [7, 8] and reviewed by Chou [9] and by Ljungman and Griffiths [10] during the Fourth International CMV Workshop (Paris, 1993). In short, peripheral blood leucocytes were isolated, cytocentrifuged and incubated with a mixture of monoclonal antibodies directed against a 65-66 kD CMV antigen, followed by immunoperoxidase staining. The number of antigen-positive cells per 50.000 leukocytes was counted in triplicate. The antigenemia assay was performed at least once weekly starting on postoperative day (pod) 12. In all patients the antigenemia was followed by either seroconversion (primary infection) or significant rise (reactivation) in CMV IgG antibodies. IgM and IgG CMV antibodies were measured quantitatively by ELISA using late stage CMV-infected fibroblasts as antigens [11].

Intestinal permeability was measured with the LM test at pod 10 after transplantation to avoid the possible bias of the postoperative state. Those values are referred as baseline values. During active CMV infection, diagnosed by a positive antigenemia assay, the intestinal permeability was measured again (median day pod 40). In five patients we were able to perform more than one permeability test during CMV infection, in the analysis we used the result of the test with the highest LM ratio. Since we measured the LM ratios during CMV infection on median day pod 40 we also measured LM ratios on median pod 40 in a control group of renal transplant recipients without CMV.

Statistical analysis was performed using the Wilcoxon signed rank test and the Mann-Whitney U test. Differences in creatinine clearances were evaluated by student's *t*-test.

### 3.3 RESULTS

We performed 104 lactulose mannitol tests (LM) test on pod 10 (baseline values), 18 during active CMV infection and 9 on pod 40 without CMV infection. Twenty-nine patients (29%) contracted an active CMV infection, 14 secondary infections versus 15 primary ones. In twelve of them the intestinal permeability was tested at least once during infection (7 secondary versus 5 primary infections). In this group 5 patients were asymptomatic and 4 had fever as the only symptom, while 3 had fever as well as leukocytopenia and thrombocytopenia. Ten of these 12 patients were hospitalized. The other 17 patients with CMV infection refused to undergo a LM test. Of these 17 patients 15 were hospitalized. They did not differ clinically from the group that was tested. In none of the 29 patients with an active CMV infection was clinical gastrointestinal symptomatology apparent. Compared to baseline values, the LM ratio increased during active CMV infection in 9 out of the 12 patients that could be studied. For these 12 patients a significant increase ( $P < 0.01$ ) was observed from a median of 0.030 (range 0.004-0.056) to 0.060 (range 0.013-0.279; figure 3.1). In addition, the LM ratio during active CMV infection was significantly ( $P < 0.01$ ) higher than in the control patients measured at pod 40 (median 0.007, range 0.004-0.032; figure 3.2). No correlation could be found between the LM ratio and clinical signs of infection, the height of antigenemia or humoral immune response. Control patients had a significantly ( $P < 0.05$ ) better renal function than the CMV patients on pod 10 (mean creatinine clearance (CrCl) on pod 10: 61 vs. 40 ml/min). During CMV infection there was a tendency towards a lower CrCl in the CMV group than in the control group on pod 40 (mean CrCl 49 vs. 64ml/min) but this did not reach statistical significance. The tendency towards a slightly higher CrCl in patients without CMV infection was most likely caused by the more frequent rejection episodes in the CMV group. The mean CrCl on pod 10 compared to pod 40 did not differ significantly in the two groups (40 vs. 49 ml/min in the CMV group and 61 vs. 64 ml/min in the control group).

Figure 3.1 Individual (●) and median (-) lactulose mannitol (LM) excretion ratios in renal transplant recipients before (postoperative day (POD) 10) and during active CMV infection (median POD 40).





Figure 3.2 Individual (●) and median (-) lactulose mannitol (LM) excretion ratios in renal transplant recipients during CMV infection (median postoperative day (POD) 40) and a control group without CMV infection (POD 40).





### 3.4 DISCUSSION

Our data appear to support involvement of the gastrointestinal tract during active CMV infection in renal transplant patients in absence of gastrointestinal symptoms. This may indicate that the majority of patients with active CMV have subclinical enteropathy as evidenced by an increased permeability of the intestinal barrier. Previous studies have shown that about a quarter of patients with reactivation of CMV after liver transplantation has evidence of CMV in their upper gastrointestinal mucosa [12]. This study suggests that the impact of CMV infection on bowel mucosa may be much more extensive than those previous studies showed.

The LM-test was used because it is simple and considered to be not stressful for patients. The LM differential permeability test has been shown to provide useful clinical information on small intestinal pathology as for example in inflammatory bowel disease or celiac disease [3]. Nevertheless there is still confusion about the permeation pathways of lactulose and mannitol. Lactulose is a disaccharide that probably diffuses between the epithelial cells of the intestinal barrier (paracellularly) through a relatively small population of large pores formed by tight junctions and extrusion zones. Mannitol is a smaller molecule and diffuses between but also across the epithelial cells (transcellularly) through a larger population of small pores. This explains why mannitol permeation is more than 30 times higher than that of lactulose. Intestinal disease makes the barrier leakier and less selective, thus favoring lactulose and increasing the LM ratio.

Although intestinal participation in CMV infection is in accordance with the systemic nature of this type of infection, the reason for the increased intestinal permeability remains speculative and requires further studies. Aside from the cytopathic effects of the virus itself on the intestinal mucosa, it has been suggested that a more widespread infection of endothelial cells by the CMV might play a pivotal role in the pathophysiology of CMV infection, possibly explaining the protean symptomatology of the infection [13, 14]. The virus is latent in tissue cells of the transplanted organ or of the recipient. The virus may be reactivated as a result of immunosuppression in the transplanted patient. According to our hypothesis, the virus most likely spreads from cell to cell until, at some point during this process endothelial cells become infected. In the following phase mononuclear and polymorphonuclear leucocytes will adhere to the infected endothelium and ingest the virus and the pp65 matrix protein, which has been proven to be the viral protein detected in the CMV antigenemia test [15]. Finally, the infected endothelial cells detach and can be seen in the blood as circulating, cytomegalic endothelial cells [13, 14]. Endothelial damage causing microvascular obstruction or plugging of these large circulating CMV-

infected endothelial cells may damage the integrity of the intestinal epithelial cells by hypoxemia and may explain the increased intestinal permeability in CMV infection. A variant on this hypothesis could be that the virus infects the enterocytes, causing cellular damage and loss of barrier function.

Clinical implications of the increased permeability can only be speculated. One important implication could be increased permeation of antigens during CMV infection or translocation of bacteria that could influence the delicate immune balance in transplant recipients, and be the cause of opportunistic infections. Another implication could be an altered absorption of drugs.

In conclusion, an increased intestinal permeability indicating intestinal epithelial damage has been found in a substantial number of patients with active CMV infection after renal transplantation. While this finding does not, in our opinion, provide any useful, marker of CMV infection, it could provide some insight into the pathophysiology of the protean manifestations of CMV infection after transplantation. Further studies need to be performed to clarify the pathophysiological mechanisms and implications of this phenomenon.

### 3.5 REFERENCES

1. Son, W.J. van, E.J. van der Jagt, F.J. van der Woude, M.H. Slooff, S. Meijer, T.H. The, A.M. Tegzess, L.B. van der Slikke, A.J.M. Donker. Pneumatosis intestinalis in patients after cadaveric kidney transplantation: possible relationship with an active cytomegalovirus infection. *Transplantation* 1984; 38:506-510.
2. Son, W.J. van, A.M. Tegzess, T.H. The, J. Duipmans, M.J.H. Slooff, T.W. van der Mark, R. Peset. Pulmonary dysfunction is common during a cytomegalovirus infection after renal transplantation, even in asymptomatic patients: possible relationship with complement activation. *The American Review of Respiratory Disease* 1987; 136:580-585.
3. Travis, S., I. Menzies. Intestinal permeability functional assessment and significance. *Clinical Science* London, England 1992; 82:471-488.
4. Laker, M.F. Estimation of disaccharides in plasma and urine by gas-liquid chromatography. *Journal of Chromatography, Biomedical Applications* 1979; 163:9-18.
5. Laker, M.F., J.N. Mount. Mannitol estimation in biological fluids by gas-liquid chromatography of trimethylsilyl derivatives. *Clinical Chemistry* 1980; 26:441-443.
6. Cobden, I., I. Hamilton, J. Rothwell, A.T. Axon. Cellobiose/mannitol test: physiological properties of probe molecules and influence of extraneous factors. *Clinica Chimica Acta* 1985; 148:53-62.
7. Bij, W. van der, R. Torensma, W.J. van Son, J. Anema, J. Schirm, A.M. Tegzess, T.H. The. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. *Journal of Medical Virology* 1988; 25:179-188.
8. Bij, W. van der, J. Schirm, R. Torensma, W.J. van Son, A.M. Tegzess, T.H. The. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. *Journal of Clinical Microbiology*, 1988; 26:2531-2535.
9. Chou, S. Molecular diagnostic techniques for CMV infection. In: S. Michelson, S.A. Plotkin (eds). *Multidisciplinary approach to understanding cytomegalovirus disease*. Excerpta Medica 1993, Elsevier Science Publishers, Amsterdam, 1993; 183-194.
10. Ljungman, P., P. Griffiths. Definitions of cytomegalovirus infection and disease. In: S. Michelson, S.A. Plotkin (eds) *Multidisciplinary approach to understanding cytomegalovirus disease*. Excerpta Medica, Elsevier Science Publishers, Amsterdam, 1993; 233-237.

11. Giessen, M. van der, A.P. van den Berg, W. van der Bij, S. Postma, W.J. van Son, T.H. The. Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenemia and disease activity in kidney recipients with active cytomegalovirus infection. *Clinical and Experimental Immunology* 1990; 80:56-61.
12. Sakr, M., T. Hassanein, J. Gavalier, K. Abu-Elmagd, J. Fung, R. Gordon, T. Starzl, D. van Thiel. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation - incidence, location, and severity in cyclosporine- and FK506-treated patients. *Transplantation* 1992; 53:786-791.
13. Grefte, J.M.M., M. van der Giessen, W.J. van Son, T.H. The. Circulating human cytomegalovirus (HCMV)-infected endothelial cells in patients with an active HCMV infection. *Journal of Infectious Diseases* 1993; 167:270-277.
14. Grefte, J.M.M., N. Blom, M. van der Giessen, W.J. van Son, T.H. The. Ultrastructural analysis of circulating cytomegalic cells in patients with active cytomegalovirus infection: evidence for virus production and endothelial origin. *The Journal of Infectious Diseases* 1993; 168:1110-1118.
15. Grefte, J.M.M., B.T.F. van der Gun, S. Schmolke, M. van der Giessen, W.J. van Son, B. Plachter, G. Jahn, T.H. The. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. *The Journal of General Virology* 1992; 73:2923-2932.